收费全文 | 6939篇 |
免费 | 465篇 |
国内免费 | 273篇 |
耳鼻咽喉 | 51篇 |
儿科学 | 84篇 |
妇产科学 | 99篇 |
基础医学 | 979篇 |
口腔科学 | 176篇 |
临床医学 | 367篇 |
内科学 | 1417篇 |
皮肤病学 | 191篇 |
神经病学 | 390篇 |
特种医学 | 131篇 |
外国民族医学 | 1篇 |
外科学 | 863篇 |
综合类 | 890篇 |
预防医学 | 413篇 |
眼科学 | 78篇 |
药学 | 662篇 |
1篇 | |
中国医学 | 201篇 |
肿瘤学 | 683篇 |
2024年 | 11篇 |
2023年 | 82篇 |
2022年 | 134篇 |
2021年 | 194篇 |
2020年 | 153篇 |
2019年 | 314篇 |
2018年 | 252篇 |
2017年 | 181篇 |
2016年 | 182篇 |
2015年 | 200篇 |
2014年 | 349篇 |
2013年 | 400篇 |
2012年 | 318篇 |
2011年 | 450篇 |
2010年 | 377篇 |
2009年 | 434篇 |
2008年 | 435篇 |
2007年 | 529篇 |
2006年 | 364篇 |
2005年 | 374篇 |
2004年 | 263篇 |
2003年 | 260篇 |
2002年 | 178篇 |
2001年 | 171篇 |
2000年 | 133篇 |
1999年 | 117篇 |
1998年 | 71篇 |
1997年 | 69篇 |
1996年 | 52篇 |
1995年 | 51篇 |
1994年 | 33篇 |
1993年 | 25篇 |
1992年 | 22篇 |
1991年 | 23篇 |
1990年 | 11篇 |
1989年 | 11篇 |
1986年 | 10篇 |
1985年 | 32篇 |
1984年 | 67篇 |
1983年 | 44篇 |
1982年 | 52篇 |
1981年 | 37篇 |
1980年 | 41篇 |
1979年 | 32篇 |
1978年 | 32篇 |
1977年 | 10篇 |
1976年 | 22篇 |
1975年 | 27篇 |
1974年 | 15篇 |
1973年 | 11篇 |
Methods: Hybrid cells containing a fragment of human chromosome 8 in scid cells (RD13B2) were used. DNA-PK activity was measured by an in vitro assay. Immunoprecipitation of the nuclear extract was performed with an anti-Ku80 antibody. Proteins co-precipitated with Ku80 were separated by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis and detected by Western blotting using anti-heat shock protein (HSP)72 and anti-heat shock cognate protein (HSC)73 antibodies. HSC73 was overexpressed with the pcDNA3.1 vector. Short hairpin (sh)RNA was used to downregulate HSC73 and HSP72.
Results: The activity of heat-inactivated DNA-PK recovered to about 50% of control during an additional incubation at 37?°C after heat treatment at 44?°C for 15?min in the presence of cycloheximide (which inhibits de novo protein synthesis). Maximal recovery was observed within 3?h of incubation at 37?°C after heat treatment. Constitutively expressed HSC73, which folds newly synthesized proteins, reached maximal levels 3?h after heat treatment using a co-immunoprecipitation assay with the Ku80 protein. Inhibiting HSC73, but not HSP72, expression with shRNA decreased the recovery of DNA-PK activity after heat treatment.
Conclusions: These results suggest that de novo protein synthesis is unnecessary for recovery of some heat-inactivated DNA-PK. Rather, it might be reactivated by the molecular chaperone activity of HSC73, but not HSP72. 相似文献
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)